Provided by Tiger Trade Technology Pte. Ltd.

MiMedx Group, Inc.

3.81
-0.1300-3.30%
Post-market: 3.810.00000.00%17:41 EDT
Volume:1.27M
Turnover:4.89M
Market Cap:564.27M
PE:11.91
High:3.98
Open:3.91
Low:3.81
Close:3.94
52wk High:7.99
52wk Low:3.81
Shares:148.10M
Float Shares:108.77M
Volume Ratio:0.79
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3200
EPS(LYR):0.3200
ROE:21.61%
ROA:13.17%
PB:2.20
PE(LYR):11.91

Loading ...

MiMedx Group (MDXG) Gets a Buy from Lake Street

TIPRANKS
·
Jan 20

MiMedx price target lowered to $10 from $12 at Lake Street

TIPRANKS
·
Jan 20

Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings

Simply Wall St.
·
Jan 09

MiMedx Secures Exclusive U.S. Distribution Agreement for RegenKit-Wound Gel

Reuters
·
Dec 22, 2025

MiMedx Enters Into Exclusive U.S. Distribution Agreement for Regenkit®-Wound Gel

THOMSON REUTERS
·
Dec 22, 2025

MiMedx (MDXG): Fresh Clinical Evidence Spurs a Closer Look at the Stock’s Valuation and Long-Term Upside Potential

Simply Wall St.
·
Dec 22, 2025

How New Immunomodulation Data on Placental Allografts Will Impact MiMedx Group (MDXG) Investors

Simply Wall St.
·
Dec 20, 2025

MiMedx Publishes Study Showing Immunomodulatory Benefits of Amniotic Membrane Allografts

Reuters
·
Dec 19, 2025

Rpt-Lantheus Holdings Inc : Mizuho Raises Target Price to $72 From $60

THOMSON REUTERS
·
Dec 17, 2025

Rpt-Inspire Medical Systems Inc : Mizuho Raises Target Price to $130 From $110

THOMSON REUTERS
·
Dec 17, 2025

Rpt-Haemonetics Corp : Mizuho Raises Target Price to $90 From $75

THOMSON REUTERS
·
Dec 17, 2025

Lake Street Keeps Their Buy Rating on MiMedx Group (MDXG)

TIPRANKS
·
Nov 24, 2025

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG) and The Ensign Group (ENSG)

TIPRANKS
·
Nov 24, 2025

MiMedx Group (MDXG) Is Down 8.4% After Strong CAMPAIGN Trial Results for EPIEFFECT Product – What's Changed

Simply Wall St.
·
Nov 22, 2025

Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)

TIPRANKS
·
Nov 14, 2025

MiMedx Provides Update on Epieffect® Randomized Controlled Trial

THOMSON REUTERS
·
Nov 13, 2025

MiMedx Chief Commercial Officer Kimberly Maersk-Moller Reports Sale of Common Shares

Reuters
·
Nov 11, 2025

MiMedx Group to Join Craig-Hallum Alpha Select and Canaccord MedTech Investor Conferences

Reuters
·
Nov 11, 2025

MiMedx comments on CY26 Medicare PFS final rule

TIPRANKS
·
Nov 03, 2025

MiMedx Q3 2025 Earnings Call Summary and Q&A Highlights: Record Growth and Strategic Positioning Amid Reimbursement Reforms

Earnings Call
·
Oct 31, 2025